

Silvana Grasso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5443241/publications.pdf>

Version: 2024-02-01

65
papers

2,196
citations

201385

27
h-index

233125

45
g-index

73
all docs

73
docs citations

73
times ranked

2014
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of Peptidomimetics with a Vinyl Sulfone Warhead as Irreversible Falcipain-2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 988-996.	2.9	196
2	Synthesis and Anticonvulsant Activity of Novel and Potent 6,7-Methylenedioxyphthalazin-1(2H)-ones. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 2851-2859.	2.9	193
3	Falcipain-2 inhibitors. <i>Medicinal Research Reviews</i> , 2010, 30, 136-167.	5.0	121
4	1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: A Novel AMPA Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 1258-1269.	2.9	88
5	Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. , 2018, 182, 176-192.		76
6	Novel Peptidomimetics Containing a Vinyl Ester Moiety as Highly Potent and Selective Falcipain-2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2157-2160.	2.9	73
7	Novel Peptidomimetic Cysteine Protease Inhibitors as Potential Antimalarial Agents. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3064-3067.	2.9	71
8	GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. <i>European Journal of Pharmacology</i> , 1995, 294, 411-422.	1.7	63
9	1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 4427-4430.	1.0	59
10	Synthesis and Anticonvulsant Activity of Novel and Potent 2,3-Benzodiazepine AMPA/Kainate Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4414-4421.	2.9	48
11	Development of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome Inhibitors. <i>ChemMedChem</i> , 2011, 6, 1228-1237.	1.6	47
12	Peptide-Based Proteasome Inhibitors in Anticancer Drug Design. <i>Medicinal Research Reviews</i> , 2014, 34, 1001-1069.	5.0	46
13	Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6911-6923.	2.9	46
14	Nonpeptidic Vinyl and Allyl Phosphonates as Falcipain-2 Inhibitors. <i>ChemMedChem</i> , 2008, 3, 1030-1033.	1.6	44
15	Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997, 356, 48-55.	1.4	40
16	7,8-Methylenedioxy-4H-2,3-benzodiazepin-4-ones as novel AMPA receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 971-976.	1.0	39
17	Synthesis and in vitro antitumour activity evaluation of 1-aryl-1H,3H-thiazolo[4,3-b]quinazolines. <i>European Journal of Medicinal Chemistry</i> , 2000, 35, 1115-1119.	2.6	37
18	Development of Rhodesain Inhibitors with a Bromoisoxazoline Warhead. <i>ChemMedChem</i> , 2013, 8, 2070-2076.	1.6	37

#	ARTICLE	IF	CITATIONS
19	Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases. <i>Current Medicinal Chemistry</i> , 2016, 23, 1217-1238.	1.2	36
20	Synthesis and anticonvulsant properties of 2,3,3a,4-tetrahydro-1H-pyrrolo[1,2-a]benzimidazol-1-ones. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 93-95.	2.9	35
21	Synthesis, Chiral Resolution, and Enantiopharmacology of a Potent 2,3-Benzodiazepine Derivative as Noncompetitive AMPA Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 575-581.	2.9	35
22	Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 3228-3233.	2.6	34
23	Development of peptidomimetic boronates as proteasome inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 64, 23-34.	2.6	34
24	Synthesis and antitumor activity of 1,3-benzodioxole derivatives. <i>Il Farmaco</i> , 2002, 57, 853-859.	0.9	31
25	Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4928-4938.	1.4	31
26	Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2058-2065.	2.6	30
27	Synthesis and Biological Evaluation of Papain-Family Cathepsin-Like Cysteine Protease Inhibitors Containing a 1,4-Benzodiazepine Scaffold as Antiprotozoal Agents. <i>ChemMedChem</i> , 2014, 9, 1817-1825.	1.6	30
28	Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6505-6511.	1.4	28
29	Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7053-7060.	1.4	28
30	Synthesis and anticonvulsant activity of new 2,3-benzodiazepines as AMPA receptor antagonists. <i>Il Farmaco</i> , 1999, 54, 178-187.	0.9	27
31	Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents. <i>Medicinal Chemistry Research</i> , 2012, 21, 2644-2651.	1.1	27
32	Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipain-2 Inhibitors. <i>ChemMedChem</i> , 2012, 7, 1594-1600.	1.6	27
33	Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2014, 83, 1-14.	2.6	27
34	Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 1184-1191.	2.5	27
35	Identification of a new series of amides as non-covalent proteasome inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2014, 76, 1-9.	2.6	25
36	Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-ones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 463-466.	1.0	24

#	ARTICLE	IF	CITATIONS
37	New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 167-170.	1.0	23
38	Structure-activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: Identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 2200-2211.	1.4	23
39	Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3453-3456.	1.0	23
40	Mechanism of Inhibition of the GluR2 AMPA Receptor Channel Opening by 2,3-Benzodiazepine Derivatives. <i>Biochemistry</i> , 2008, 47, 1061-1069.	1.2	22
41	Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 578-591.	2.6	21
42	Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. <i>Note II. Il Farmaco</i> , 2003, 58, 351-355.	0.9	19
43	Development of novel N-3-bromoisoxazolin-5-yl substituted 2,3-benzodiazepines as noncompetitive AMPAR antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3631-3637.	1.4	18
44	Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes. <i>ChemMedChem</i> , 2019, 14, 842-852.	1.6	18
45	Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 443-446.	1.0	17
46	Mechanism of Inhibition of GluA2 AMPA Receptor Channel Opening by 2,3-Benzodiazepine Derivatives: Functional Consequences of Replacing a 7,8-Methylenedioxy with a 7,8-Ethylenedioxy Moiety. <i>Biochemistry</i> , 2012, 51, 1787-1795.	1.2	17
47	Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents. <i>ChemMedChem</i> , 2014, 9, 1801-1816.	1.6	16
48	Novel Potent AMPA/Kainate Receptor Antagonists: Synthesis and Anticonvulsant Activity of a Series of 2-[(4-Alkylsemicarbazono)-(4-amino-phenyl)methyl]-4,5-methylenedioxyphenylacetic Acid Alkyl Esters. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4433-4442.	2.9	14
49	Synthesis and Characterization of Isomeric 2,3,3a,4-Tetrahydro-1H-pyrrolo[1,2-a]benzimidazol-1-ones from 1,2-Phenylenediamines and 3-Acylpropionic Acids. <i>Heterocycles</i> , 1988, 27, 93.	0.4	14
50	Separation of the enantiomers of anticonvulsant tricyclic pyrroloimidazolones by enantioselective HPLC. A chiral recognition model and a chiroptical study. <i>Tetrahedron: Asymmetry</i> , 1996, 7, 2577-2584.	1.8	12
51	A SIMPLE AND EFFICIENT SYNTHESIS OF GYKI 52466 AND GYKI 52895. <i>Synthetic Communications</i> , 2002, 32, 527-533.	1.1	12
52	Design of 1-substituted 2-arylmethyl-4,5-methylenedioxybenzene derivatives as antiseizure agents. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 3703-3709.	1.4	10
53	NMR conformational analysis in solution of a potent class of cysteine proteases inhibitors. <i>Structural Chemistry</i> , 2015, 26, 943-950.	1.0	10
54	Anticonvulsant activity of pyrrolo[1,2-a]imidazo[4,5-b]pyridines, pyrrolo[2,1-f]imidazo[4,5-c]pyridines and pyrrolo[2,1-f]purines in DBA/2 mice. <i>General Pharmacology</i> , 1994, 25, 1027-1031.	0.7	8

#	ARTICLE	IF	CITATIONS
55	Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 278-283.	1.0	8
56	Mechanism and Site of Inhibition of AMPA Receptors: Substitution of One and Two Methyl Groups at the 4-Aminophenyl Ring of 2,3-Benzodiazepine and Implications in the α -Site. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1371-1378.	1.7	7
57	Compounds with potential anti-tumor activity VII. Synthesis and anti-tumor activity of 1-aryl-N,N ϵ -di(1,3,4-thiadiazol-2-yl)methylenediamines. <i>European Journal of Medicinal Chemistry</i> , 1989, 24, 131-135.	2.6	6
58	Synthesis of 2-semicarbazonomethyl-4,5-methylenedioxyphenylacetic acids as anticonvulsant agents. <i>Il Farmaco</i> , 2005, 60, 231-235.	0.9	6
59	Synthesis of Novel 3-(Alkylcarbamoyl)-2-aryl-1,2-dihydro-6,7-(methylenedioxy)-3H-quinazolin-4-ones as Anticonvulsant Agents. <i>Chemistry and Biodiversity</i> , 2006, 3, 304-311.	1.0	4
60	7-Chloro-1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole and 1-(2,6-difluorophenyl)-6-methyl-1H,3H-thiazolo[3,4-a]benzimidazole. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 2001, 57, 572-574.	0.4	3
61	Enantioseparation, absolute configuration determination, and anticonvulsant activity of (\pm)-1-(4-aminophenyl)-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-one. <i>Chirality</i> , 2007, 19, 16-21.	1.3	3
62	Synthesis and Cytotoxic Activity of 1,3-Benzodioxole Derivatives. Part 2.. <i>ChemInform</i> , 2003, 34, no.	0.1	1
63	Synthesis, Chiral Resolution and Pharmacological Evaluation of a 2,3-Benzodiazepine-Derived Noncompetitive AMPA Receptor Antagonist. <i>ChemMedChem</i> , 2009, 4, 415-420.	1.6	1
64	Synthesis and Antitumor Activity of 1,3-Benzodioxole Derivatives.. <i>ChemInform</i> , 2003, 34, no.	0.1	0
65	1-Aryl-6,7-methylenedioxy-3H-quinazolin-4-ones as Anticonvulsant Agents.. <i>ChemInform</i> , 2004, 35, no.	0.1	0